

**Examiner-Initiated Interview Summary**

Application No.

09/931,325

Applicant(s)

BIRKETT, ASHLEY J.

Examiner

Zachariah Lucas

Art Unit

1648

**All Participants:****Status of Application:** \_\_\_\_\_(1) Zachariah Lucas.

(3) \_\_\_\_\_

(2) Edward P. Gamson.

(4) \_\_\_\_\_

**Date of Interview:** 25 May 2004**Time:** \_\_\_\_\_**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

NA

Claims discussed:

1, 9, 27, 35, 56, 60, 61, 62, 64

Prior art documents discussed:

NA

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet***Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
(Examiner/SPE Signature)\_\_\_\_\_  
(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner indicated that the claims could be placed into condition for allowance with certain amendments to clarify the claim language.

First, it was suggested that claims 1, 27, and 60 be amended such that part (a) of the claims (defining Domain I), reads follows:

-- (a) Domain I comprises (i) the HBc sequence from position 1 through position 75, or (ii) a sequence of about 85 amino acids comprising a sequence heterologous to HBc peptide-bonded to one of the first five N-terminal residues of HBc, and including at least the sequence of the residues of position 5 through position 75 of HBc; -- .

Second, it was suggested that claims 1, 27, and 60 be amended such that lines 1-3 of part (b) of the claims (describing Domain II) reads as follows:

-- (b) Domain II comprises about 18 to about 58 amino acid residues peptide bonded to residue 75 of HBc, including (i) the sequence of HBc positions 76 through 85, and --;

and such that claims 9, 35, 56, 61, and 64 be amended such that lines 1-3 of part (b) of the claims (describing Domain II) reads as follows:

-- (b) Domain II comprises about 18 to about 46 amino acid residues peptide bonded to residue 75 of HBc, including (i) the sequence of HBc positions 76 through 85, and --;

and that claim 62 be amended in lines 2-4, such that it reads on the vaccine of claim 60 -- wherein Domain II comprises about 18 to about 46 amino acid residues peptide-bonded to residue 75 of HBc, including (i) the sequence of HBc positions 76 through 85, and -- .

The first amendment is intended to clarify what is meant by the phrase "to about 85 amino acids." The second set of amendments are intended to clarify the language of subpart (b).

The Applicant indicated that these changes were acceptable, and that they could be made by Examiner's Amendment.